Skip to main content
PMC home page
Elsevier - PMC COVID-19 Collection logoLink to Elsevier - PMC COVID-19 Collection
. 2009 Jul 11;105(9):743–752. doi: 10.1016/S0929-6646(09)60202-3

Safety and Effectiveness of Rosiglitazone in Type 2 Diabetes Patients with Nonalcoholic Fatty Liver Disease

Chao-Hung Wang 1, Ching-Hsiang Leung 1, Sung-Chen Liu 1,*, Cheng-Ho Chung 1
PMCID: PMC7134933  PMID: 16959622

Abstract

Background/Purpose

Nonalcoholic fatty liver disease (NAFLD) is a common chronic liver disease ranging in severity from steatosis to cirrhosis. Type 2 diabetes mellitus is a cause of primary NAFLD. Thiazolidinediones have been shown to enhance insulin sensitivity, improve glycemic control in type 2 diabetes patients and to improve the histologic markers of nonalcoholic steatohepatitis. This study aims to determine the safety and effectiveness of rosiglitazone in inadequately controlled type 2 diabetes patients with NAFLD.

Methods

Taiwanese type 2 diabetes patients with inadequate control on insulin secretagogues and metformin, with no history of significant alcohol ingestion, with mildly elevated serum aspartate amino-transferase (AST) and/or alanine aminotransferase (ALT) and a diagnosis of fatty liver determined by ultrasonography were enrolled. Patients were treated for 24 weeks with rosiglitazone, 4-8 mg daily. Primary endpoints were change in AST and ALT levels from baseline and reduction in A1C < 6.5%.

Results

Out of a total of 68 patients, 60 (88.2%) completed the study treatment without serious adverse events. Treatment in two (2.9%) patients was discontinued due to elevated AST or ALT levels to more than three times the upper limit of normal, and noncompliance or loss of follow-up in six (8.8%) patients. Of the 60 patients who completed the study treatment, mean fasting plasma glucose, A1C, fasting plasma insulin, mean ALT and homeostasis model assessment for insulin resistance were all significantly reduced. Normal AST and ALT levels were achieved and maintained for at least three consecutive measurements and through to the end of the study period in 20 (33.3%) patients. Weight increased by a mean of 2.6 ± 2.4 kg (p<0.001).

Conclusion

Rosiglitazone was reasonably well tolerated in patients with inadequately controlled type 2 diabetes and NAFLD. One-third of patients showed improved liver function after treatment.

Key Words: nonalcoholic fatty liver disease, rosiglitazone, thiazolidinediones, type 2 diabetes

References

  • 1.Matteoni CA, Younossi ZM, Gramlich T. Nonalcoholic fatty liver disease: a spectrum of clinical pathological severity. Gastroenterology. 1999;116:1413–1419. doi: 10.1016/s0016-5085(99)70506-8. [DOI] [PubMed] [Google Scholar]
  • 2.Festi D, Colecchia A, Sacco T. Hepatic steatosis in obese patients: clinical aspects and prognostic significance. Obes Rev. 2004;5:27–42. doi: 10.1111/j.1467-789x.2004.00126.x. [DOI] [PubMed] [Google Scholar]
  • 3.Marchesini G, Brizi M, Morselli-Labate AM. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med. 1999;107:450–455. doi: 10.1016/s0002-9343(99)00271-5. [DOI] [PubMed] [Google Scholar]
  • 4.Chitturi S, Abeygunasekera S, Farrell GC. NASH and insulin resistance: insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology. 2002;35:373–379. doi: 10.1053/jhep.2002.30692. [DOI] [PubMed] [Google Scholar]
  • 5.Marchesini G, Bugianesi E, Forlani G. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology. 2003;37:917–923. doi: 10.1053/jhep.2003.50161. [DOI] [PubMed] [Google Scholar]
  • 6.Salt WB., II Nonalcoholic fatty liver disease (NAFLD): a comprehensive review. J Insur Med. 2004;36:27–41. [PubMed] [Google Scholar]
  • 7.Phillips LS, Grunberger G, Miller E. Once- and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes. Diabetes Care. 2001;24:308–315. doi: 10.2337/diacare.24.2.308. [DOI] [PubMed] [Google Scholar]
  • 8.Lebovitz HE, Dole JF, Patwardhan R. Rosiglitazone monotherapy is effective in patients with type 2 diabetes. J Clin Endocrinol Metab. 2001;86:280–288. doi: 10.1210/jcem.86.1.7157. [DOI] [PubMed] [Google Scholar]
  • 9.Miyazaki Y, Mahankali A, Matsuda M. Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone. Diabetes Care. 2001;24:710–719. doi: 10.2337/diacare.24.4.710. [DOI] [PubMed] [Google Scholar]
  • 10.Mayerson AB, Hundal RS, Dufour S. The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes. Diabetes. 2002;51:797–802. doi: 10.2337/diabetes.51.3.797. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Miyazaki Y, Mahankali A, Matsuda M. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab. 2002;87:2784–2791. doi: 10.1210/jcem.87.6.8567. [DOI] [PubMed] [Google Scholar]
  • 12.Carey DG, Cowin GJ, Galloway GJ. Effect of rosiglita-zone on insulin sensitivity and body composition in type 2 diabetic patients. Obes Res. 2002;10:1008–1015. doi: 10.1038/oby.2002.137. [DOI] [PubMed] [Google Scholar]
  • 13.Bajaj M, Suraamornkul S, Pratipanawatr T. Pioglita-zone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes. Diabetes. 2003;52:1364–1370. doi: 10.2337/diabetes.52.6.1364. [DOI] [PubMed] [Google Scholar]
  • 14.Neuschwander-Terri BA, Brunt EM, Wehmeier KR. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-r ligand rosiglitazone. Hepatology. 2003;38:1008–1017. doi: 10.1053/jhep.2003.50420. [DOI] [PubMed] [Google Scholar]
  • 15.Caldwell SH, Hespenheide EE, Redick JA. A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis. Am J Gastroenterol. 2001;96:519–525. doi: 10.1111/j.1572-0241.2001.03553.x. [DOI] [PubMed] [Google Scholar]
  • 16.Tolman KG, Chandramouli J. Hepatotoxicity of the thiazo-lidinediones. Clin Liver Dis. 2003;7:367–379. doi: 10.1016/s1089-3261(03)00020-5. [DOI] [PubMed] [Google Scholar]
  • 17.Lebovitz HE, Kreider M, Freed MI. Evaluation of liver function in type 2 diabetic patients during clinical trials: evidence that rosiglitazone does not cause hepatic dysfunction. Diabetes Care. 2002;25:815–821. doi: 10.2337/diacare.25.5.815. [DOI] [PubMed] [Google Scholar]
  • 18.Rubin CJ, Schneider RL. Pioglitazone liver enzyme profiles is similar in placebo in US controlled clinical trials. Diabetes. 2000;49:A123. [Google Scholar]
  • 19.Promrat K, Lutchman G, Uwaifo GI. A pilot study of pioglitazone treatment for non alcoholic steatohepatitis. Hepatology. 2004;39:188–196. doi: 10.1002/hep.20012. [DOI] [PubMed] [Google Scholar]
  • 20.Matthews DR, Hosker JP, Rudenski AS. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentration in man. Diabetologia. 1985;28:412–419. doi: 10.1007/BF00280883. [DOI] [PubMed] [Google Scholar]
  • 21.Dailey GE, III, Noor MA, Park JS. Glycemic control with glyburide/metformin tablets in combination with rosiglitazone in patients with type 2 diabetes: a randomized, double blind trial. Am J Med. 2004;116:223–229. doi: 10.1016/j.amjmed.2003.07.022. [DOI] [PubMed] [Google Scholar]
  • 22.Day C, James O. Steatohepatitis: a tale of two “hits”? Gastroenterology. 1998;114:842–845. doi: 10.1016/s0016-5085(98)70599-2. [DOI] [PubMed] [Google Scholar]
  • 23.Marceau P, Biron S, Hould FS. Liver pathology and the metabolic syndrome X in severe obesity. J Clin Endocrinol Metab. 1999;84:1513–1517. doi: 10.1210/jcem.84.5.5661. [DOI] [PubMed] [Google Scholar]
  • 24.Pavo I, Jermendy G, Varkonyi TT. Effect of pioglita-zone compared with metformin on glycemic control and indicators of insulin sensitivity in recently diagnosed patients with type 2 diabetes. J Clin Endocrinol Metab. 2003;88:1637–1645. doi: 10.1210/jc.2002-021786. [DOI] [PubMed] [Google Scholar]
  • 25.Hanefeld M, Brunetti P, Schernthaner GH. One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes. Diabetes Care. 2004;27:141–147. doi: 10.2337/diacare.27.1.141. [DOI] [PubMed] [Google Scholar]
  • 26.Aronoff S, Rosenblatt S, Braithwaite S. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes. Diabetes Care. 2000;23:1605–1611. doi: 10.2337/diacare.23.11.1605. [DOI] [PubMed] [Google Scholar]
  • 27.Kipnes MS, Krosnick A, Rendell MS. Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study. Am J Med. 2001;111:10–17. doi: 10.1016/s0002-9343(01)00713-6. [DOI] [PubMed] [Google Scholar]
  • 28.Einhorn D, Rendell M, Rosenzweig J. Pioglita-zone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. Clin Ther. 2000;22:1395–1409. doi: 10.1016/s0149-2918(00)83039-8. [DOI] [PubMed] [Google Scholar]
  • 29.Aljabri K, Kozak SE, Thompson DM. Addition of pioglita-zone or bedtime insulin to maximal doses of sulfonylurea and metformin in type 2 diabetes patients with poor glucose control: a prospective, randomized trial. Am J Med. 2004;116:230–235. doi: 10.1016/j.amjmed.2003.07.023. [DOI] [PubMed] [Google Scholar]
  • 30.Miyazaki Y, Pipek R, Mandarino LJ. Tumor necrosis factor a and insulin resistance in obese type 2 diabetic patients. Int J Obesity. 2003;27:88–94. doi: 10.1038/sj.ijo.0802187. [DOI] [PubMed] [Google Scholar]
  • 31.Spiegelman BM. PPAR-?: adipogenic regulator and thia-zolidinedione receptor. Diabetes. 1998;47:507–514. doi: 10.2337/diabetes.47.4.507. [DOI] [PubMed] [Google Scholar]
  • 32.Tonelli J, Li W, Kishore P. Mechanism of early insulin-sensitizing effects of thiazolidinediones in type 2 diabetes. Diabetes. 2004;53:1621–1629. doi: 10.2337/diabetes.53.6.1621. [DOI] [PubMed] [Google Scholar]
  • 33.Haffner SM, Greenberg AS, Weston WM. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes melli-tus. Circulation. 2002;106:679–684. doi: 10.1161/01.cir.0000025403.20953.23. [DOI] [PubMed] [Google Scholar]
  • 34.Mohanty P, Aljada A, Ghanim H. Evidence for a potent antiinflammatory effect of rosiglitazone. J Clin Endocrinol Metab. 2004;89:2728–2735. doi: 10.1210/jc.2003-032103. [DOI] [PubMed] [Google Scholar]
  • 35.Natali A, Ferrannini E. Hypertension, insulin resistance, and the metabolic syndrome. Endocrinol Metab Clin North Am. 2004;33:417–429. doi: 10.1016/j.ecl.2004.03.007. [DOI] [PubMed] [Google Scholar]
  • 36.American Gastroenterological Association AGA technical review on nonalcoholic fatty liver disease. Gastroenterology. 2002;123:1705–1725. doi: 10.1053/gast.2002.36572. [DOI] [PubMed] [Google Scholar]
  • 37.Quinn SF, Gosink BB. Characteristic sonographic signs of hepatic infiltration. Am J Roentgenol. 1985;145:753–755. doi: 10.2214/ajr.145.4.753. [DOI] [PubMed] [Google Scholar]
  • 38.Mulhall BP, Ong JP, Younossi ZM. Non-alcoholic fatty liver disease: an overview. J Gastroenterol Hepatol. 2002;17:1136–1143. doi: 10.1046/j.1440-1746.2002.02881.x. [DOI] [PubMed] [Google Scholar]

Articles from Journal of the Formosan Medical Association are provided here courtesy of Elsevier

RESOURCES